Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
Amy S. Paller(Northwestern University), Sonya Cyr(Regeneron (United States)), Annie Zhang(AVEO Oncology (United States)), Andreas Wollenberg(University Hospital Augsburg), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(University of Rochester Medicine), Ashish Bansal(Regeneron (United States)), Elaine C. Siegfried(Saint Louis University), Zhen Chen(The First People's Hospital of Shunde), Jignesh Vakil(Sanofi (United States)), Faisal A. Khokhar(Regeneron (United States)), Michael J. Cork(Royal Hallamshire Hospital)
Cited by 46
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k